CR11031A - Composiciones de enzima digestiva estable - Google Patents

Composiciones de enzima digestiva estable

Info

Publication number
CR11031A
CR11031A CR11031A CR11031A CR11031A CR 11031 A CR11031 A CR 11031A CR 11031 A CR11031 A CR 11031A CR 11031 A CR11031 A CR 11031A CR 11031 A CR11031 A CR 11031A
Authority
CR
Costa Rica
Prior art keywords
digestive enzyme
enzyme compositions
stable digestive
stable
compositions
Prior art date
Application number
CR11031A
Other languages
English (en)
Inventor
Giovanni Ortenzi
Marco Marconi
Luigi Mapelli
Original Assignee
Eurand Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Pharmaceuticals Ltd filed Critical Eurand Pharmaceuticals Ltd
Publication of CR11031A publication Critical patent/CR11031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Las composiciones de la presente invencion, que comprenden por lo menos una enzima digestiva (por ejemplo, pancrelipasa) son utiles para tratar o evitar trastornos asociados con deficiencias de enzima digestiva.
CR11031A 2007-02-20 2009-09-17 Composiciones de enzima digestiva estable CR11031A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90209107P 2007-02-20 2007-02-20
US90209207P 2007-02-20 2007-02-20
US90209307P 2007-02-20 2007-02-20

Publications (1)

Publication Number Publication Date
CR11031A true CR11031A (es) 2009-12-30

Family

ID=39637607

Family Applications (2)

Application Number Title Priority Date Filing Date
CR11031A CR11031A (es) 2007-02-20 2009-09-17 Composiciones de enzima digestiva estable
CR20140422A CR20140422A (es) 2007-02-20 2014-09-16 Composiciones de enzima digestiva estable

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20140422A CR20140422A (es) 2007-02-20 2014-09-16 Composiciones de enzima digestiva estable

Country Status (27)

Country Link
US (9) US8221747B2 (es)
EP (2) EP2754437B1 (es)
JP (2) JP5966202B2 (es)
KR (2) KR101837010B1 (es)
CN (2) CN103933555B (es)
AR (1) AR065405A1 (es)
AU (1) AU2008218595B2 (es)
BR (1) BRPI0807718B1 (es)
CA (1) CA2677989C (es)
CL (1) CL2008000517A1 (es)
CO (1) CO6220903A2 (es)
CR (2) CR11031A (es)
DK (1) DK2079445T3 (es)
ES (2) ES2560527T3 (es)
HK (1) HK1142818A1 (es)
HU (1) HUE026168T2 (es)
IL (1) IL200407A (es)
MX (1) MX2009008828A (es)
MY (1) MY163469A (es)
NZ (2) NZ579047A (es)
PL (1) PL2079445T3 (es)
PT (1) PT2079445E (es)
SG (1) SG186648A1 (es)
TR (1) TR201808840T4 (es)
TW (2) TWI421090B (es)
WO (1) WO2008102264A2 (es)
ZA (1) ZA200905630B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
CA2616943C (en) 2005-07-29 2016-04-12 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
MY163469A (en) 2007-02-20 2017-09-15 Allergan Therapeutics LLC Stable digestive enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US7782646B2 (en) * 2008-06-30 2010-08-24 International Business Machines Corporation High density content addressable memory using phase change devices
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2373296B1 (en) 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
ES2882518T3 (es) 2009-01-06 2021-12-02 Galenagen Llc Composición que comprende proteasa, amilasa y lipasa
ES2727746T3 (es) 2009-01-06 2019-10-18 Galenagen Llc Composiciones orales para el tratamiento o la prevención de infecciones por E. Coli
PL2391382T3 (pl) * 2009-01-29 2014-11-28 Nordmark Arzneimittel Gmbh & Co Kg Preparat farmaceutyczny zawierający lipazę pochodzenia bakteryjnego
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CN102421288B (zh) * 2009-05-07 2015-04-22 联合治疗公司 前列环素类似物的固体剂型
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
WO2011072069A2 (en) * 2009-12-08 2011-06-16 Depomed, Inc. Gastric retentive pharmaceutical compositions for extended release of polypeptides
US20110224648A1 (en) 2010-03-15 2011-09-15 Angelo Secci Syringe Filter Cap and Method of Using the Same for Administration of Medication Dosage
KR20130050923A (ko) * 2010-03-19 2013-05-16 앱탈리스 파마 캐나다 아이엔씨. 위 내성 효소 제약 조성물
CN102946872A (zh) * 2010-05-03 2013-02-27 阿普塔利斯制药有限公司 包含含有胰酶的消化酶混合物的微丸组合物
UY33548A (es) * 2010-08-06 2012-02-29 Eurand Pharmaceuticals Inc Formula nutricional predigerida
CA2810243C (en) 2010-09-15 2021-04-20 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2812862C (en) * 2010-10-01 2018-11-20 Aptalis Pharma Limited Enteric coated, low-strength pancrelipase formulations
TW201216951A (en) 2010-10-21 2012-05-01 Aptalis Pharma Ltd Oral dosing device for administration of medication
EP3056197A1 (en) * 2010-11-19 2016-08-17 Curemark, Llc Preparation and use of combination enzyme and gastrointestinal modulator delivery systems
AU2012245287B2 (en) 2011-04-21 2017-04-13 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
JP2012250926A (ja) * 2011-06-01 2012-12-20 Nitto Denko Corp 粒子製剤
US9216209B1 (en) * 2011-06-06 2015-12-22 Kilmer S. McCully Compositions and method for utilization of thioretinamide in therapy of degenerative diseases of aging
DK2741766T3 (en) 2011-08-08 2016-01-11 Aptalis Pharma Ltd Process for dissolving solid compositions containing digestive enzymes
CN102357088A (zh) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 盐酸二甲双胍肠溶片
TWI434706B (zh) 2011-12-15 2014-04-21 Ind Tech Res Inst 腸溶及腸酵素可分解材料及其製備方法
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
JP6263540B2 (ja) * 2012-09-19 2018-01-17 グレスポ・アクチボラゲットＧｒｅｓｐｏ ＡＢ 脳機能向上用組成物
JP6244793B2 (ja) * 2012-10-24 2017-12-13 味の素株式会社 蛋白質含有食品の製造方法及び蛋白質含有食品改質用の酵素製剤
EP2996712B1 (en) * 2013-03-15 2018-10-31 Allergan Pharmaceuticals International Limited Process for the preparation of a composition containing digestive enzymes and nutrients suitable for enteral administration
US20160152927A1 (en) 2013-06-25 2016-06-02 Conopco, Inc., D/B/A Unilever Detergent composition comprising glutamic-n, n-diacetate (glda), water and enzyme
AU2014306222A1 (en) 2013-08-09 2016-02-18 Aptalis Pharma Ltd. Digestive enzyme composition suitable for enteral administration
KR20170052520A (ko) * 2013-11-05 2017-05-12 앨러간 파마슈티컬스 인터내셔널 리미티드 고효능 판크레아틴 약학적 조성물
CZ307195B6 (cs) 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
CA2947998A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
CN104531659B (zh) * 2014-12-16 2018-05-22 四川新健康成生物股份有限公司 胰蛋白酶消化液、制备方法及即用型痰消化装置
GB201501081D0 (en) * 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
WO2017052455A1 (en) 2015-09-23 2017-03-30 Anara Ab Amylase fragments for blood glucose control
CA3019482A1 (en) * 2016-03-31 2017-10-05 Vhsquared Limited Compositions
EP3251687A1 (en) 2016-06-01 2017-12-06 Centrum Innowacji Edoradca Sp. z o.o. Spolka Komandytowa Bioactive peptides for blood glucose control
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
CN108977429B (zh) * 2018-09-14 2021-08-03 中国水产科学研究院黄海水产研究所 一种海洋微生物ys2071脂肪酶稳定性保护剂
US20230056445A1 (en) 2019-06-21 2023-02-23 Sorriso Pharmaceuticals, Inc. Polypeptides
US20220242945A1 (en) 2019-06-21 2022-08-04 Sorriso Pharmaceuticals, Inc. Polypeptides
US11541009B2 (en) * 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN113749086A (zh) * 2021-08-27 2021-12-07 佛山科学技术学院 DNase I及其药学上可接受的盐在制备精液稀释的药物中的应用
WO2023168316A1 (en) * 2022-03-04 2023-09-07 Michael Ogburn Enteric coated dry powdered cannabinoid formulations

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19417A (en) * 1858-02-23 Improvement in cotton-gins
US24660A (en) * 1859-07-05 Setting gas-meteks in the walls of buildings
US44968A (en) * 1864-11-08 Improvement in couplings for whiffletrees
US101562A (en) * 1870-04-05 Chaeles alden
US2751330A (en) 1952-08-27 1956-06-19 Armour & Co Use of a salt in the extraction slurry in recovering proteolytic enzymes from pancreas gland material
GB1342409A (en) 1970-07-23 1974-01-03 Ciba Geigy Ag Flowable pancreatin preparation of low microorgan ism content and a process for its manufacture
US4237229A (en) 1975-06-10 1980-12-02 W. R. Grace & Co. Immobilization of biological material with polyurethane polymers
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
GB1590432A (en) 1976-07-07 1981-06-03 Novo Industri As Process for the production of an enzyme granulate and the enzyme granuate thus produced
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
DE2923279B1 (de) 1979-06-08 1980-11-20 Kali Chemie Pharma Gmbh Verfahren zur Herstellung von Pankreatin-Pellets
JPS5855125B2 (ja) 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
JPS5885159A (ja) 1981-11-17 1983-05-21 Furointo Sangyo Kk 溶出試験装置
EP0115023B1 (de) 1982-12-30 1988-07-27 Nordmark Arzneimittel GmbH Verfahren zur Gewinnung von Pankreatin
US4447412A (en) 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
DE3445301A1 (de) * 1984-12-12 1986-06-12 Hoechst Ag, 6230 Frankfurt Pankreasenzympraeparate und verfahren zu deren herstellung
DE3689727T2 (de) 1985-12-27 1994-07-07 Showa Denko Kk Granulierungsverfahren für enzyme.
DE3750369T2 (de) * 1986-03-21 1995-05-24 Eurasiam Lab Arzneimittelzusammensetzungen.
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
FR2603804B1 (fr) 1986-09-17 1989-10-27 Jouveinal Sa Lipases et extraits lipasiques, leur procede de preparation et leur application en therapeutique
IT1205716B (it) * 1987-01-21 1989-03-31 Samil Spa Procedimento per la preparazione di microsfere gastroresistenti ed enterosolubili di enzima digestivo e preparato faramceutico a microsfere cosi' prodotto
DK435687D0 (da) 1987-08-21 1987-08-21 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
US5733763A (en) 1988-08-19 1998-03-31 Novo Nordisk A/S Enzyme granulate formed of an enzyme-containing core and an enzyme-containing shell
DK78189D0 (da) 1989-02-20 1989-02-20 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
DK78089D0 (da) 1989-02-20 1989-02-20 Novo Industri As Detergentholdigt granulat og fremgangsmaade til fremstilling deraf
DK306289D0 (da) 1989-06-21 1989-06-21 Novo Nordisk As Detergentadditiv i granulatform
DE3927286C2 (de) 1989-08-18 1997-07-24 Roehm Gmbh Wäßrige Enzym-Flüssigformulierungen
CA2030581C (en) * 1989-11-24 2000-06-27 Gunther Atzl Pancreatin preparations
IT1246350B (it) * 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
JPH0790565B2 (ja) 1991-08-06 1995-10-04 株式会社日本製鋼所 樹脂成形プレスのスライド制御方法及びその装置
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
WO1993007859A1 (en) 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
HRP930935A2 (en) 1992-06-11 1994-12-31 Astra Ab New dna sequences
US5578304A (en) * 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5460812A (en) 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
JP3264027B2 (ja) 1993-02-24 2002-03-11 ソニー株式会社 放電セル及びその製造方法
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
RU94017352A (ru) 1994-05-11 1996-07-27 Товарищество с ограниченной ответственностью "Инвест" Способ лечения онкологических больных, перенесших операцию на желудочно-кишечном тракте
DE4422433A1 (de) 1994-06-28 1996-01-04 Cognis Bio Umwelt Mehrenzymgranulat
DE69523757T2 (de) 1994-08-05 2002-08-01 West Pharm Serv Cornall Ltd Behälter für feuchtickeitsempfindliche stoffe und entsprechendes verfahren zum trocknen und zur reduktion
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
ES2236738T3 (es) 1995-05-31 2005-07-16 Medzyme N.V. Composicion para mejorar la digestibilidad y la utilizacion de nutrientes.
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
DE19622131A1 (de) 1996-06-01 1997-12-04 Solvay Enzymes Gmbh & Co Kg Neue Enzymgranulate
CA2257106C (en) 1996-06-04 2002-04-23 Euro-Celtique, S.A. Improvements in detection systems and methods for predicting the dissolution curve of a drug from a pharmaceutical dosage form
JPH1023888A (ja) 1996-07-10 1998-01-27 Kao Corp 酵素造粒物の製造方法
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
GB9623205D0 (en) 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
CA2198317C (en) 1997-02-24 2003-01-07 Mouhsine El Abboudi Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof
JPH10295374A (ja) 1997-04-30 1998-11-10 Amano Pharmaceut Co Ltd 安定な酵素顆粒の製造法
DE19721467A1 (de) 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
SE9702338D0 (sv) 1997-06-18 1997-06-18 Astra Ab An analytical method and industrial process including the same
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
JPH11315043A (ja) 1998-04-30 1999-11-16 Lion Corp ヒドロキシエーテル化合物の製造方法及び洗浄剤組成物
US20010024660A1 (en) 1999-09-29 2001-09-27 Ismat Ullah Enteric coated pharmaceutical composition and method of manufacturing
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
HU230454B1 (hu) 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
EP1224272B1 (en) 1999-10-01 2005-12-07 Novozymes A/S Spray dried enzyme product
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
WO2001070047A1 (en) 2000-03-24 2001-09-27 Société des Produits Nestlé S.A. Nutritional composition comprising hydrolysed protein
AU2001244093A1 (en) 2000-04-03 2001-10-15 Novozymes A/S Enzyme tablets for cleaning improvement
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
ATE346590T1 (de) 2001-07-26 2006-12-15 Ethypharm Sa Umgehüllte allylamine oder benzylamine enthaltende granulate, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die umgehüllten granulate
JP4187085B2 (ja) 2001-08-24 2008-11-26 三菱電機株式会社 車両用乗員保護装置
US20040197321A1 (en) 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
CN1156308C (zh) 2002-04-19 2004-07-07 北京世诺医药科技有限公司 多酶组合胶囊
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2003288988A1 (en) 2002-11-29 2004-06-23 Freund Corporation Water-based shellac coating material, process for producing the same, coated food obtained with the coating material, process for producing the same, coated medicine, process for producing the same, glazing composition for oily snack, method of glazing, and glazed oily snack
CA2419572A1 (en) 2003-02-18 2004-08-18 Axcan Pharma Inc. High dosage protease formulation
US20040213847A1 (en) 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
US6955520B2 (en) * 2003-07-22 2005-10-18 Delaware Capital Formation, Inc. Refuse collection vehicle and method with stackable refuse storage container
EP1682168B1 (en) 2003-10-29 2013-05-01 Eli Lilly And Co. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
JP5032300B2 (ja) 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060198838A1 (en) 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
UA91521C2 (ru) 2004-10-14 2010-08-10 Элтус Фармасьютикалз Инк. Композиции, содержащие липазу, протеазу и амилазу, предназначенные для лечения недостаточности поджелудочной железы
US20070025977A1 (en) 2005-07-21 2007-02-01 Mulberg Andrew E Method of treating steatorrhea in infants
KR101199196B1 (ko) 2005-07-25 2012-11-07 (주)다산메디켐 구형의 판크레아틴 과립의 제조방법
CA2616943C (en) 2005-07-29 2016-04-12 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
MX2008001557A (es) 2005-08-15 2008-02-15 Solvay Pharm Gmbh Nucleos de microglobulos de pancreativa adecuados para revestimiento enterico.
DK1931316T4 (en) 2005-08-15 2017-05-15 Abbott Laboratories Gmbh Controlled-release pharmaceutical compositions for use in acid-labile drugs
WO2007053619A2 (en) 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
WO2007074856A1 (ja) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤の製造法
US20070190142A1 (en) * 2006-01-21 2007-08-16 Abbott Gmbh & Co. Kg Dosage forms for the delivery of drugs of abuse and related methods
EP2021011A2 (en) 2006-05-26 2009-02-11 Nestec S.A. Methods of use and nutritional compositions of touchi extract
CN103168928A (zh) 2006-08-07 2013-06-26 诺维信公司 用于动物饲料的酶团粒
KR100804096B1 (ko) 2006-08-31 2008-02-18 (주)아모레퍼시픽 고농도 계면활성제 계에서도 안정한 효소 캡슐 제제를포함하는 피부 세정용 조성물 및 그 제조방법
JP5038731B2 (ja) 2007-01-23 2012-10-03 株式会社ハタ研削 光分岐接続装置
US20080199448A1 (en) 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
MY163469A (en) 2007-02-20 2017-09-15 Allergan Therapeutics LLC Stable digestive enzyme compositions
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
RU2445952C2 (ru) 2007-02-20 2012-03-27 Юранд Фармасьютикалз Лимитед Стабильные композиции пищеварительных ферментов
WO2008127567A1 (en) 2007-04-13 2008-10-23 Beth Israel Deaconess Medical Center, Inc. Novel nutritional food products for improved digestion and intestinal absorption
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
CN101430279A (zh) 2008-10-27 2009-05-13 江南大学 荧光分光光度法筛选催化非水相体系转酯化反应用酶的方法
US8784884B2 (en) 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
JP2011093845A (ja) 2009-10-29 2011-05-12 宏之 ▲今▼西 胃瘻用注入剤及びその注入装置
WO2011072069A2 (en) 2009-12-08 2011-06-16 Depomed, Inc. Gastric retentive pharmaceutical compositions for extended release of polypeptides
KR20130050923A (ko) 2010-03-19 2013-05-16 앱탈리스 파마 캐나다 아이엔씨. 위 내성 효소 제약 조성물
US9283578B2 (en) 2010-04-14 2016-03-15 Dow Global Technologies Llc Dispensing device for both froth and non-froth coatings
GB201006178D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
UY33548A (es) 2010-08-06 2012-02-29 Eurand Pharmaceuticals Inc Formula nutricional predigerida
TW201210517A (en) 2010-08-06 2012-03-16 Aptalis Pharma Ltd Predigested nutritional formula
CA2812862C (en) 2010-10-01 2018-11-20 Aptalis Pharma Limited Enteric coated, low-strength pancrelipase formulations
TW201216951A (en) 2010-10-21 2012-05-01 Aptalis Pharma Ltd Oral dosing device for administration of medication
GB2492284B (en) 2011-03-27 2013-07-17 Cellresin Tech Llc Cyclodextrin compositions, articles, and methods
DK2741766T3 (en) 2011-08-08 2016-01-11 Aptalis Pharma Ltd Process for dissolving solid compositions containing digestive enzymes
CN103060296B (zh) 2012-12-30 2014-05-21 青岛九龙生物医药有限公司 从动物胰脏中提取胰蛋白酶的方法
EP2996712B1 (en) 2013-03-15 2018-10-31 Allergan Pharmaceuticals International Limited Process for the preparation of a composition containing digestive enzymes and nutrients suitable for enteral administration
CA2919114A1 (en) 2013-07-22 2015-02-12 Aptalis Pharma Ltd. High potency pancreatin pharmaceutical compositions
AU2014306222A1 (en) 2013-08-09 2016-02-18 Aptalis Pharma Ltd. Digestive enzyme composition suitable for enteral administration
KR20170052520A (ko) 2013-11-05 2017-05-12 앨러간 파마슈티컬스 인터내셔널 리미티드 고효능 판크레아틴 약학적 조성물
CA2947998A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts

Also Published As

Publication number Publication date
EP2754437A2 (en) 2014-07-16
ZA200905630B (en) 2011-06-29
AU2008218595B2 (en) 2012-05-24
TWI609693B (zh) 2018-01-01
MY163469A (en) 2017-09-15
CL2008000517A1 (es) 2008-08-08
US8562979B2 (en) 2013-10-22
US8562981B2 (en) 2013-10-22
US8293229B2 (en) 2012-10-23
US20110123634A1 (en) 2011-05-26
ES2560527T3 (es) 2016-02-19
PT2079445E (pt) 2016-02-29
MX2009008828A (es) 2009-12-14
US8246950B2 (en) 2012-08-21
CN103933555A (zh) 2014-07-23
CR20140422A (es) 2014-10-28
AU2008218595A1 (en) 2008-08-28
JP2014074053A (ja) 2014-04-24
US10206882B2 (en) 2019-02-19
KR20150038322A (ko) 2015-04-08
US20110123633A1 (en) 2011-05-26
DK2079445T3 (en) 2016-02-15
IL200407A0 (en) 2010-04-29
HK1142818A1 (en) 2010-12-17
BRPI0807718A2 (pt) 2014-05-20
US8562978B2 (en) 2013-10-22
JP6082691B2 (ja) 2017-02-15
US20100270183A1 (en) 2010-10-28
PL2079445T3 (pl) 2016-04-29
TW201422233A (zh) 2014-06-16
EP2754437B1 (en) 2018-04-11
AR065405A1 (es) 2009-06-03
KR101837010B1 (ko) 2018-03-09
TWI421090B (zh) 2014-01-01
US8221747B2 (en) 2012-07-17
BRPI0807718B1 (pt) 2021-08-10
JP2010519217A (ja) 2010-06-03
ES2674681T3 (es) 2018-07-03
US20140170212A1 (en) 2014-06-19
US7658918B1 (en) 2010-02-09
CN101686943B (zh) 2014-03-26
CN103933555B (zh) 2018-06-01
US20080274174A1 (en) 2008-11-06
CA2677989A1 (en) 2008-08-28
US20080299185A1 (en) 2008-12-04
CO6220903A2 (es) 2010-11-19
US20100021537A1 (en) 2010-01-28
WO2008102264A2 (en) 2008-08-28
TW200843795A (en) 2008-11-16
NZ579047A (en) 2012-03-30
JP5966202B2 (ja) 2016-08-10
US20080279953A1 (en) 2008-11-13
IL200407A (en) 2017-01-31
EP2079445A2 (en) 2009-07-22
WO2008102264A3 (en) 2009-07-23
EP2079445B1 (en) 2015-11-04
NZ598477A (en) 2012-11-30
EP2754437A3 (en) 2015-07-01
HUE026168T2 (en) 2016-05-30
KR20090122254A (ko) 2009-11-26
SG186648A1 (en) 2013-01-30
KR101670016B1 (ko) 2016-10-27
US8562980B2 (en) 2013-10-22
WO2008102264A8 (en) 2008-10-16
TR201808840T4 (tr) 2018-07-23
CN101686943A (zh) 2010-03-31
US20110123605A1 (en) 2011-05-26
CA2677989C (en) 2018-04-24

Similar Documents

Publication Publication Date Title
CR11031A (es) Composiciones de enzima digestiva estable
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
CR20110103A (es) Heteroarilos sustituidos
CR10310A (es) Compuestos nuevos
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
EA200701918A1 (ru) Белок липокалин
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
GT200900146A (es) Inhibidores de la actividad de la akt
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
CR8978A (es) Proteinas de fusion de dominio de union
DOP2009000281A (es) Moleculas pequeñas que contienen boro
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PA8667201A1 (es) Nuevos compuestos farmaceuticos
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
PA8720401A1 (es) Metodos para tratar trastornos cognitivos y otros afines